Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil.
Tália Santana Machado de AssisAna RabelloGláucia CotaGuilherme Loureiro WerneckAndré Luís Ferreira de Azeredo-da-SilvaPublished in: Revista da Sociedade Brasileira de Medicina Tropical (2019)
These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.